Member Info for B2HS2L

Monty

..."that can materially effect the SP estimated to be more than 10% per the listing rules"

Is that both AIM AND bourse rules please?

Poidster -
"Paris, France and Camberley, UK - 4 May 2021 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT; "Novacyt"), an international clinical diagnostics company, will donate one million COVID-19 polymerase chain reaction (PCR) tests to UNICEF to help contain the spread of the virus through testing. "

Assay unidentified.
If NHS weren't fond of exsig direct, it may be that assay.

https://www.bbc.co.uk/news/business-58656292

News from USA concerning hospitalised Covid patients.
An ICU nurse (friend of my sister in law) works in a Tennessee hospital.
She states the majority of Covid patients admitted are not vaccinated.
ICU patients who have been vaccinated have a higher chance of recovery.
The hospital is using refrigerated trucks (plural) to store the deceased as temporary storage.

IMO settling the dispute (regardless of how), will herald attempts to buyout this company.
GM has ensured that each and every new product or process, plus all of the unprotected stuff purchased with IT-IS International, now has a patent application, so they will now count when attempts to value the company occur.
Of course best case, big pharma end up in a bidding war, but it is far from clear who and how many will be interested.

There will be those who badly want access to the R&D team for their own purposes, likewise the genomic sequencers and their modus operandi and contacts.
Others will be interested in the Point of Care instruments and assays.

PROmate is patent applied for, and differentiates Novacyt's assays from other companies tests, (faster and with simplified work flow). One SNPsig product uses a PROmate workflow, - SNPsig SARS CoV-2 (E484K) Easy.

I don't have a timeline for dispute settlement, but expect a step change in sp when resolution announced.

The test is a simple blood test that research has shown is particularly effective at finding cancers that are typically difficult to identify early – such as head and neck, bowel, lung, pancreatic, and throat cancers.

https://www.england.nhs.uk/2021/09/nhs-launches-world-first-trial-for-new-cancer-test/

Sounds like the sort of project we would have been interested in starting ourselves.

https://ckclinical.co.uk/revolutionary-nhs-early-detection-cancer-trials-launch-through-help-of-ck-group/

Companies house info has this as a micro private company.
Very interesting write - up.

14.09.2021 -
Healthcare software entrepreneurs Clive Minihan and Andrew Halliday have had a busy 16 months.
Predicting that the need to process COVID tests at scale would require the process to be digitised, the pair formed the start-up Recova-19 in May 2020.

https://www.med-technews.com/medtech-insights/medtech-start-up-insights/how-a-covid-testing-portal-sparked-a-new-venture/

++++
Their testing portal has now facilitated the processing of more than 1.2 million tests
++++

Word-search Recova on this website:
https://www.boots.com/health-pharmacy-advice/covid-19-testing/covid-19-testing-service
++++
The Recova-19 company was incorporated in May 2020 & is a spin off of CCL, who use Novacyt assays.
https://youcontrol.com.ua/en/catalog/gb-card/12588824/

Seems like Novacyt has benefitted mightily here.

https://www.linkedin.com/in/gemma-stokes/

I take this to mean that new Genomic Sequencing assay design takes place at Southampton, not Stratford-on-avon.

Covido -
"Nobody leaves an opportunity on the table like this that long."
So why is it that AFAWK we have not had a serious offer?
IMO it is probable not possible that we have had low offers, but NO CREDIBLE OFFERS?
Shareholders are not being told of all significant contracts.
vis:
https://novacyt.com/wp-content/uploads/2021/09/NVT-SOC-companys-activity.pdf
• Secured significant contracts with national governments, including the UK DHSC, and national nongovernment organisations for the supply of COVID-19 products

Likewise we are not being advised of significant M&A interest.
There is probably plenty of insignificant interest I'll be bound.
+++

source: https://www.linkedin.com/in/biograd-diagnostics-040094108/

"BioGrad Diagnostics process up to 15,000 Covid-19 tests a day, offering tests for Pre-Travel, Day 2, Day 8 and Test to Release. We have clinics across the Northwest and provide a gold standard in Covid-19 screening."

+++

I wasn't aware they were this busy with NCYT assay's!

Tony Cooke Chief Executive Officer at Cambridge Clinical Laboratories :
"Here at CCL we have just launched our "direct to user" COVID testing service “C-19Direct” which you can find at c-19direct.com. We are only doing; day 2, Day 5 and Day 8 testing at the moment but this service will develop further as we add more alliance labs and further tests to the portal. We are just trying to simplify the whole process for people wanting to order travel tests and being confronted with hundreds of front-end providers. We are not planning to provide 10,000’s of tests per day but we are planning to provide a quality service at a reasonable price. So, by ordering directly from the lab it should make the process quicker, simpler, and cheaper in the long run – let’s see how it goes."

https://c-19direct.com/ :

"Covid-19 testing by UKAS accredited laboratories from the comfort of your own home."

Cambridge Clinical Laboratories (CCL)
A UKAS accredited ISO 15189 (accreditation) laboratory founded in 2005.
A private company, it has served the NHS and international customers processing tests in Oncology, Virology, Fertility, Sexual Health and Autoimmunology.
CCL is contracted to process Covid-19 tests by the Department of Health and Social Care.

Well done Tony. - I hope the alliance labs will also be introduced to Novacyt products.

Bugs14 - filtered.
One look at your posting history, and I'm certain I don't want to hear more.

Kaeren - FWIW:

From 14.05.2020 RNS - Final Results for the year ended 31 December 2019

"In addition, during the year, Primerdesign expanded its assay development contract with Immunexpress, Inc., a U.S.-based molecular diagnostic company, with the first FDA cleared host response test for suspected sepsis patients. This is to further support the development of rapid diagnostic assays for the detection of sepsis. Sepsis is a potentially life-threatening complication in which a person's immune system inappropriately responds to an infection by triggering a broader inflammatory response, which could cause damage to multiple organs and ultimately lead to death. Left undiagnosed or untreated, a patient could die within a matter of hours. This contract expansion adds further momentum to our B2B segment and provides further validation of the expertise our clinical assay development service offers."

a) They don't actually need a vote for share buy backs as they have one already, they could issue an RNS tomorrow confirming a buy back but they are asking us to vote yet again because more chance it will happen later i guess.
+++++

French law limits the number of shares that may be repurchased to 10% of the company’s capital (or 5% in
the event that they will be used as consideration in a merger transaction). The authority to repurchase shares
cannot be granted for a period of time exceeding 18 months.

++++

IMO they are seeking a fresh 18 month buy-back period.

HarChris -
We are replacing a techie with a Sales and Marketing wiz.
I would be very surprised if there was not a very quick change in priorities and attitudes.
I have not come across many sales and marketing staff who are not trumpeting something they intend to sell to someone.
Whether that means the revs and sales figs we only get to review once every 6 months will be updated monthly remains to be seen.
Will we get to hear USA progress - don't think so, but the baseline change I seek is to hear about contract wins when they happen.

Apologies if posted before, - about a month old:
https://www.linkedin.com/feed/update/urn:li:activity:6828726150420828162/

I like the LGC field application specialists comment, - very apt at the moment.

Rav -
A logical extension of your guesswork might be that Novacyt aren't extending any credit to DHSC whilst the dispute has not ended. Strictly cash with order?

If that is what is happening, AJ R is nowhere near full time on Novacyt assay development.

Good spot EXMEX, - another facility in Cardiff.
We should assume then that room has been found amongst the other R&D projects for the assay development service the vacancy discusses. Or perhaps that service has been operating from S-o-A since January?

If AJ is key to all other ongoing projects, it's the only place he can be located, - hence why Novacyt genomic assay team are resident?